Bilal Khan

Bilal Khan has over 20 years of experience in leadership and actuarial roles in the medical and financial sectors. Currently serving as Chief Executive Officer of New World Medical since August 2008, Bilal Khan oversees the development of innovative technologies such as the Ahmed Glaucoma Valve and STREAMLINE Surgical System. In addition to this role, Bilal Khan is President & Chief Executive Officer of SpyGlass Pharma, Inc., and has previously held positions such as Member of the Board of Directors and Board Observer with the same company, along with chairing the Board of Directors at AIG. Bilal Khan's earlier career includes actuarial and analytical positions at prominent organizations such as Transamerica, Towers Watson, Mercer, and PwC. Bilal Khan holds an MBA from The Wharton School and a Bachelor of Business Administration in Actuarial Science from the Wisconsin School of Business.